21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017...
20:34 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest nanoparticles loaded with siRNAs targeting SOX2 , OLIG2 , SALL2 , and POU3F2 could help treat the proneural subtype of glioblastoma multiforme (GBM). In two proneural...
17:35 , May 25, 2017 |  BC Innovations  |  Emerging Company Profile

Total reprogramming

University of Cambridge spinout Elpis Biomed Ltd. has a platform that rapidly produces stockpiles of pure, mature cell types from human pluripotent stem cells. While the company is first focusing on creating well-defined disease models,...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
14:16 , Apr 18, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Cell models A method for differentiating hPSCs into specific cell types by expressing select transcription factors could aid the development of cell-based disease models. The method involved engineering hPSCs via CRISPR-associated protein 9 (Cas9)-guided...
07:00 , May 19, 2014 |  BioCentury  |  Emerging Company Profile

Curtana: Curtains for CSCs

Curtana Pharmaceuticals Inc. is developing small molecule inhibitors of OLIG2 , a transcription factor that may maintain cancer stem cells that help glioblastoma multiforme resist and bounce back from cancer therapy. GBM was seen as...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

Curtana Pharmaceuticals, University of California deal

In September, newco Curtana received exclusive, worldwide rights to preclinical small molecule inhibitors against oligodendrocyte transcription factor 2 (OLIG2) from the university to treat glioblastoma multiforme and other cancers. Curtana plans to submit an IND...
07:00 , May 16, 2013 |  BC Innovations  |  Tools & Techniques

Myelination gets direct

Separate groups at the Case Western Reserve University School of Medicine and the Stanford University School of Medicine have developed similar approaches to directly reprogram rodent fibroblasts into oligodendrocyte progenitor cells. 1,2 The direct lineage...
07:00 , May 2, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Fibroblast-derived induced oligodendrocyte progenitor cells (iOPCs) to treat myelination disorders Two separate studies developed methods to reprogram mouse fibroblasts into iOPCs...
08:00 , Nov 6, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology; stroke Oligodendrocyte lineage transcription factor 2 (OLIG2) Studies in mice suggest that modulating OLIG2 expressed by proliferating astrocytes in the...